EU Pharma Wants Staggered Approach For Direct Data Capture In Clinical Trials
The European pharmaceutical industry feels the European Medicines Agency's recent opinion on the regulatory acceptability of using eSource Direct Data Capture in clinical trials is promising, but that not all EU countries would be ready for its uptake in the near future.
You may also be interested in...
New treatments for advanced endometrial cancer and hereditary angioedema are among six drugs that have just been recommended for EU-wide approval. Harmonized EU advice has also been issued in relation to an investigational antibody combination for treating COVID-19.
As part of its big data initiative, the European Medicines Agency is supporting projects that will help identify appropriate real-world data sources for regulatory decision making.
The European Medicines Agency may decide this week on a dozen requests by companies seeking new uses of their approved drugs.